Zhang Jiawei, Huang Qiming, Yang Yi, Zhang Jiahui, Fang Xueting, Yang Yubin, Liang Huifang, Wang Wei, Wang Yanjun
Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Department of Medical Imaging, the Second Affiliated Hospital, Fujian Medical University, Quanzhou, China.
Cancer. 2023 Apr 1;129(7):1030-1040. doi: 10.1002/cncr.34639. Epub 2023 Jan 10.
The role of carbonic anhydrase II (CAII) in intrahepatic cholangiocarcinoma (ICC) was investigated and a novel prognostic system combining CAII and preoperative carbohydrate antigen 19-9 (CA19-9) was established to predict the survival of patients with ICC after curative resection.
A total of 110 patients who underwent curative-intent resection for ICC between 2012 and 2020 were retrospectively analyzed. CAII in tumor and peritumor regions was examined by immunohistochemistry, and the relationships between clinicopathological factors and the prognostic value of CAII and CA19-9 were analyzed.
CAII was frequently downregulated in ICC tissues (p < .001). Multivariate analyses indicated that showed that both low CAII expression level and preoperative CA19-9 ≥236 U/ml were independent risk factors for overall survival (OS) and recurrence-free survival (RFS) in patients with ICC after radical resection. Survival analysis revealed that patients with high CAII and low CA19-9 were significantly associated with a better OS and RFS (p < .001). The time-dependent receiver operating characteristic curves showed that CAII + CA19-9 had better prognostic predictive ability than CAII or CA19-9 alone. The nomogram constructed on independent factors including T stage, lymph node metastasis, CA19-9 (continuous variable), and CAII achieved C-indexes of 0.754 (95% CI, 0.701-0.807) and 0.730 (0.674-0.785) for OS and RFS, respectively. The calibration curve revealed acceptable agreement between actual and predicted OS and RFS.
The combination of CAII and preoperative CA19-9 is a novel and useful prognostic tool for predicting the survival of patients with ICC after curative resection and guiding clinical decisions.
Carbonic anhydrase II (CAII) was frequently downregulated in intrahepatic cholangiocarcinoma (ICC) tissues. Survival analysis revealed that CAII is a novel independent factor for prognosis in patients with ICC after curative resection. CAII could be a useful prognostic marker for patients with ICC after surgery. The combination of CAII and preoperative carbohydrate antigen 19-9 is a novel and useful prognostic tool for predicting the survival of patients with ICC after curative resection and guiding clinical decisions.
研究碳酸酐酶II(CAII)在肝内胆管癌(ICC)中的作用,并建立一种结合CAII和术前糖类抗原19-9(CA19-9)的新型预后系统,以预测根治性切除术后ICC患者的生存情况。
回顾性分析2012年至2020年间110例行ICC根治性切除的患者。通过免疫组织化学检测肿瘤及瘤旁组织中的CAII,并分析临床病理因素与CAII和CA19-9预后价值之间的关系。
CAII在ICC组织中常呈下调表达(p < 0.001)。多因素分析表明,低CAII表达水平和术前CA19-9≥236 U/ml均为根治性切除术后ICC患者总生存(OS)和无复发生存(RFS)的独立危险因素。生存分析显示,CAII高且CA19-9低的患者OS和RFS明显更好(p < 0.001)。时间依赖性受试者工作特征曲线显示,CAII + CA19-9比单独的CAII或CA19-9具有更好的预后预测能力。基于包括T分期、淋巴结转移、CA19-9(连续变量)和CAII在内的独立因素构建的列线图,OS和RFS的C指数分别为0.754(95%CI,0.701 - 0.807)和0.730(0.674 - 0.785)。校准曲线显示实际与预测的OS和RFS之间具有可接受的一致性。
CAII与术前CA19-9的联合是预测根治性切除术后ICC患者生存情况及指导临床决策的一种新型且有用的预后工具。
碳酸酐酶II(CAII)在肝内胆管癌(ICC)组织中常呈下调表达。生存分析显示,CAII是根治性切除术后ICC患者预后的一个新的独立因素。CAII可能是ICC术后患者有用的预后标志物。CAII与术前糖类抗原19-9的联合是预测根治性切除术后ICC患者生存情况及指导临床决策的一种新型且有用的预后工具。